Overview
Mezida Saeed practices practicing medicine in Stockholm, Sweden.
Their clinical expertise encompasses Chediak-Higashi Syndrome, Primary Immunodeficiency (PID), and Wiskott-Aldrich Syndrome.
They are actively involved in clinical research, co-authoring 13 peer reviewed articles.
Locations
Stockholm, AB, Sweden
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Mezida B. Saeed
Is Mezida B. Saeed a top-rated expert for Chediak-Higashi Syndrome?
MediFind is an objective health platform that identifies experts based on real-world data. Mezida B. Saeed is classified as an Experienced expert for Chediak-Higashi Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Mezida B. Saeed participate in research or clinical trials?
Yes. Mezida B. Saeed has published 13 articles and abstracts on conditions like Chediak-Higashi Syndrome. You can view a list of Mezida B. Saeed's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Chediak-Higashi SyndromeSaeed isExperienced. Learn about Chediak-Higashi Syndrome.
- Primary Immunodeficiency (PID)
- Wiskott-Aldrich SyndromeSaeed isExperienced. Learn about Wiskott-Aldrich Syndrome.